Development of analytical methods for the quantification of metabolites of lesogaberan in a MIST investigation

Biomedical Chromatography

Volumn 28, Issue 3, 2014, Pages 362-368

  Dunér, Kristina ^a   Bottner, Pernilla ^a   Norlén, Anna Karin ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

HILIC; Lesogaberan; Metabolites; MIST

Indexed keywords

BIOMOLECULES; BUTYRIC ACID; ELECTROSPRAY IONIZATION; HYDROPHILICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRECIPITATION (CHEMICAL);

ANALYTICAL METHOD; HILIC; HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHIES; LESOGABERAN; MIST; MOLECULE INTERACTIONS; POLAR MOLECULES; PROTEIN PRECIPITATION; QUANTITATIVE DETERMINATIONS; SEPARATION MODES;

METABOLITES;

DRUG METABOLITE; LESOGABERAN;

ANALYTIC METHOD; ARTICLE; DRUG BLOOD LEVEL; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LIMIT OF DETECTION; NEGATIVE ION ELECTROSPRAY; NONHUMAN; QUANTITATIVE ANALYSIS; REPEATED DRUG DOSE; TANDEM MASS SPECTROMETRY;

HILIC; LESOGABERAN; METABOLITES; MIST;

ANIMALS; CHROMATOGRAPHY, LIQUID; DOGS; DRUG STABILITY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MASS SPECTROMETRY; PHOSPHINIC ACIDS; PROPYLAMINES; RATS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84893630208     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3029     Document Type: Article

References (17)

1. Boeckxstaens GE, Denison H, Jensen JM, Lehmann A and Ruth M. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'. Current Opinion in Pharmacology 2011a; 1: 630-633.
2. Boeckxstaens GE, Beaumont H, Hatlebakk JG, Silberg DG, Björck K, Karlsson M and Denison H. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut 2011b; 60: 1182-1188.
3. Ekdahl A, Aurell-Holmberg A and Castagnoli Jr N. Identification of the metabolites of lesogaberan using linear trap quadrupole orbitrap mass spectrometry and hydrophilic interaction liquid chromatography. Xenobiotica 2013; 43(5): 461-467.
4. Fakt C, Jacobson BM, Leandersson S, Olsson BM and Persson BA. FaktC, Jacobson BM, Leandersson S, Olsson BM, and Persson BA. Determination of a small, highly polar aminopropylphosphinic acid as racemate in plasma and urine and as separated enantiomers in plasma by liquid chromatography and tandem mass spectrometry. Analytica Chimica Acta 2003; 492: 261-269.
5. ICH, June 2009. ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf (accessed 15 October 2012).
6. ICH, March 2012. M3(R2) guideline: guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, questions & answers (R2). Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Q_As/M3_R2_Q_A_R2_Step4.pdf (accessed 15 October 2012).
7. Jacobson BM, Olsson A, Fakt C and Öhman D. The use of human plasma as matrix for calibration standards in pre-clinical LC-MS/MS methods--a way to reduce animal use. Journal of Pharmacuetical and Biomedical Analysis 2011; 54: 826-829.
8. Jessome LL and Volmer DA. Ion suppression: a major concern for mass spectrometry. LCGC North America 2006; 24: 498-510.
9. Jian W, Xu Y, Edom R and Weng N. Analysis of polar metabolites by hydrophilic interaction chromatography-MS/MS. Bioanalysis 2011; 3: 899-912.
10. Lacy BE, Chehade R and Crowell MD. Lesogaberan. Drugs of the Future 2010; 35: 987-992.
11. Shaheen NJ, Denison H, Björck K, Karlsson M and Silberg DG. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. Gut 2013; 62(9): 1248-1255.
12. Shrake A and Rupley JA. Environment and exposure to solvent of protein atoms. Lysozyme and insulin. Journal of Molecular Biology 1973; 79: 351-371.
13. Smith G. Are multimetabolite methods fit-for-purpose for supporting toxicology studies? Bioanalysis 2011; 3: 2701-2704.
14. Smith DA and Obach RS. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chemical Research and Toxicology 2009; 22: 267-279.
15. Timmerman P, Kall MA, Gordon B, Laakso S, Freisleben A and Hucker R. Best practice in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum. Bioanalysis 2010; 2(7): 1185-1194.
16. US FDA. Guidance for industry: bioanalytical method validation, May 2001. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070107.pdf (accessed 15 October 2012).
17. US FDA. Guidance for industry: safety testing of drug metabolites, February 2008. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf (accessed 15 October 2012).